Uncategorized-EN
Vimseltinib for Tenosynovial Giant Cell Tumor (MOTION)
Trial name: Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT), MOTION study Agents: Vimseltinib vs. placebo Phase III Status Not recruiting, but active Sponsor Deciphera Pharmaceuticals This Phase 3 clinical study aims to evaluate the effectiveness of vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the…
Read MoreUnesbulin in Advanced Leiomyosarcoma (SUNRISELMS)
Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (SUNRISELMS) Agents: Unesbulin in combination with dacabazine Phase II/III Status Recruiting Sponsor PTC Therapeutics Further information: https://clinicaltrials.gov/ct2/show/NCT05269355 This study compares the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in patients with unresectable or metastatic, relapsed or refractory leiomyosarcoma (LMS) who have received at…
Read MorePalbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Ewing Sarcomas
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors incl. Ewing Sarcomas (phase II) Agents: Combination with irinotecan and temozolomide with or without palbociclib Phase II Status Closed for recruitment, but active Sponsor Pfizer Further information: https://clinicaltrials.gov/ct2/show/NCT03709680 This study is comparing the effectiveness of the study medicine palbociclib when taken in combination with chemotherapy medicines irinotecan…
Read MoreSTRASS Trial
Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma (STRASS) Agents: Radiation therapy followed by surgery vs. surgery alone Phase III Status Open, recruiting Sponsor European Organisation for Research and Treatment of Cancer – EORTC Further information Link zu Details (to be inserted) WHO is the trial…
Read MoreMitigate
The Mitigate Project Agents: A novel PET-CT tracer specifically developed to target cell surface receptors of GIST cells Phase I/IIa Status Open, recruiting Sponsor Medical University Innsbruck, European Union Further information: www.mitigate-project.eu WHO is the trial for? Patients with progressive disease who have at least been treated with imatinib are eligible The study addresses…
Read MoreCABO GIST
CABO GIST Agents: Cabozantinib Phase II Status Completed Sponsor EORTC Further information: https://clinicaltrials.gov/ct/show/NCT02216578 or http://www.eortc.org/research_field/clinical-detail/1317/ WHO is the trial for? Patients with metastatic GIST (histologically confirmed) and removed primary tumor Patients with progression during treatment of GIST (before or after surgery, with or without metastasis) with imatinib and sunitinib (but no further/other therapies) Overall…
Read MoreAbout us (2)
{loadposition position-15} Sarcoma Patients EuroNet Association (SPAEN), the international Network of Sarcoma, GIST and Desmoid Patient Advocacy Groups, was founded in April 2009 with the aim of extending information services, patient support and advocacy to patient organisations for the benefit of sarcoma patients across the whole of Europe and internationally. Acting in partnership with…
Read MoreAnnual Conferences
Previous SPAEN Conferences 8th SPAEN Annual Conference 2018 Milan/ItalyThe SPAEN Annual Conference 2018 was held – for the first time ever – in conjunction with a professional meeting. SPAEN and European Society of Medical Oncology (ESMO) have agreed to combine their meetings and hold the SPAEN conference just before the ESMO GIST & Sarcoma Symposium…
Read MoreSPAEN Advocacy in Action Award 2017: And the award goes to…
Patient advocacy ensures that people are heard, take action and ultimately improve situations, achieve changes or help to fulfil unmet medical needs. We decided that it is time to shout out about how important patient advocacy in sarcomas is – for patients, caregivers, healthcare professionals or anyone interested in sarcomas. We are very…
Read MoreCall to action: SPAEN Advocacy in Action Award 2019
SPAEN Advocacy in Action Award for best projects in sarcoma patients advocacy Patient advocacy ensures that people are heard, take action and ultimately improve situations, achieve changes or help to fulfil unmet medical needs. We believe it is time to shout out about how important patient advocacy in sarcomas is – for patients, caregivers, healthcare…
Read More